FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Biblioteca de Pilhas

Extended GH Stack

GH Optimizationadvanced

91

síntese

91
Share
Peptídeos

3

Média Diária mcg

650

Nível

advanced

Adicionado

May 17, 2026

Visão Geral

The Extended GH Stack adds IGF-1 LR3 to the classic CJC-1295 + Ipamorelin base, creating a three-tier growth hormone axis protocol that addresses GH secretion, GH release, and downstream IGF-1 signaling simultaneously. CJC-1295 and Ipamorelin handle the upstream signaling — increasing GH output through GHRH and ghrelin pathways respectively. IGF-1 LR3 (a long-acting analog of Insulin-like Growth Factor-1) enters downstream, acting directly on muscle, bone, and organ cells to drive protein synthesis, cellular hypertrophy, and tissue growth — the actual anabolic outcomes that elevated GH is designed to produce. The practical advantage of adding IGF-1 LR3 is ensuring the anabolic signal reaches peripheral tissue even when natural liver conversion of GH to IGF-1 is suboptimal — common with age, metabolic dysfunction, or intensive training loads. IGF-1 LR3 has a 20–30 hour half-life compared to native IGF-1''s minutes, providing sustained receptor activation throughout the day. This stack is for experienced users who have established a response to the classic GH stack and want to extend its downstream effects. IGF-1 LR3 is administered post-workout to direct its anabolic action toward recently trained muscle tissue. This protocol requires blood work monitoring of IGF-1 levels (often quarterly), fasting glucose, and HbA1c due to IGF-1''s insulin-like effects on glucose metabolism.

Protocolo de Dose

CJC-1295

Every day· subcutaneous

Leia mais sobre CJC-1295 →

300 mcg

por dose

Ipamorelin

Every day· subcutaneous

Leia mais sobre Ipamorelin →

300 mcg

por dose

IGF-1 LR3

daily (post-workout)· subcutaneous

Leia mais sobre IGF-1 LR3 →

50 mcg

por dose

Objetivos & Evidências

Maximum anabolismMuscle hypertrophyGH axis optimizationPerformance
Nível de Evidência:Dados Humanos

Avisos

  • IGF-1 LR3 carries significant risk if IGF-1 levels are not monitored. Contraindicated with any cancer history. Requires medical supervision.

Comments

Sign in to join the discussion

Aviso: Esta pilha é submetida pela comunidade e para fins de pesquisa apenas. Peptide Contacts não verifica a segurança ou eficácia das pilhas submetidas. Sempre consulte um profissional de saúde qualificado antes de usar qualquer protocolo com peptídeos.